Karthaus, M., Schwingel, J., Bauer, H., Ansorge, N., Barmashenko, G., Burkart, C., Ettrich, T. J., Gerhardt, A., Hoefling, S., Jacobasch, L., Koenigsmann, M., Räth, S., Schulte, M., Schulte, N., Schwarzer, A., Siegler, G. M., Waldschmidt, D., Lutz, M. P. (2025). Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.707